Stay updated with breaking news from Cell Engager. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its...
Proceeds Support Advancement of the M-gager Platform Technology and Lead Product Candidate CDR404, a First Antibody Fragment-based Dual MAGE-A4 T Cell Engager, and Other Discovery ProgramsZÜRICH, Switzerland
Investegate announcements from CDR-Life AG, CDR-Life Announces $76 Million Raised in Series A Funding
With TCEs being studied in both hematological and solid tumors (39 and 34 trials respectively), there are now more than one hundred projects in the preclinical stage.Early clinical outcomes and novel TCE design modifications have fueled the development and clinical advancement of over 65 bispecific T-cell engagers (...
On Monday, Lindis Biotech, GmbH filed a complaint in the District of Delaware against Amgen Inc. for allegedly infringing upon their patents for an